Low activity of complement in the cerebrospinal fluid of the patients with various prion diseases by Cao Chen et al.
SHORT REPORT Open Access
Low activity of complement in the
cerebrospinal fluid of the patients with
various prion diseases
Cao Chen1,2†, Yan Lv1,2†, Qi Shi1,2, Wei Zhou1,2, Kang Xiao1,2, Jing Sun1,2, Xiao-Dong Yang1,2
and Xiao-Ping Dong1,2,3*
Abstract
Background: The aim of this study was to analyze the state of activity and levels of complement in the
cerebrospinal fluid (CSF) of patients with various prion diseases (PrDs).
Findings: The proteomic data emphasized the levels of 20 known complement components found in the CSF of
the sCJD panel that were lower than those found in the non-PrD panel. 50 % of the complement hemolytic activity
(CH50) assays revealed significantly lower activity of complement in the CSF of the sCJD panel. The decreased
levels of three key complement subunits, C3a/α, C4β, and C9 in the CSF of the sCJD panel were verified by Western
blots. Furthermore, the CH50 values in the CSF of 136 sCJD, 39 gCJD, 22 FFI and 145 non-CJD patients were
individually tested. Compared with the control of non-PrD, the CH50 value in the CSF specimens of various PrDs,
especially in three subtypes of inherited PrDs, were significantly lower. Relationship analysis identified that the CH50
activity in the CSF was negatively associated with the protein 14–3–3 positive in the CSF.
Conclusion: These results indicate a silent complement system in the CSF of PrD patients.
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Background
Human prion diseases (PrDs) are a category of fatal neuro-
degenerative disorders including Creutzfeldt-Jakob disease
(CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS),
fatal familial insomnia (FFI) and Kuru [1]. Surrogate bio-
markers in CSF are screened for alterations, which not only
identify the diagnostic markers for CJD, but also provide
insight for understanding the pathogenesis. So far, only the
immunoblot for the 14–3–3 protein in CSF is included in
the diagnostic criteria for sporadic CJD (sCJD) [2].
The complement system, which consists of at least 30
kinds of soluble and membrane-bound proteins, is an
immune-defense mechanism with a wide range of effects
that take place in the central nervous system (CNS). Evi-
dence suggests that the activation of complement compo-
nents occurs in patients with various neurodegenerative
disorders [3–6], and that certain complement proteins are
deregulated during prion infection [5, 7–12]. Our previous
proteomic study has revealed that some complement
components were lower in the CSF of sCJD patients [13].
However, the exact relationship has yet to be proven.
Methods
This study was approved by the Ethical Committee of
the National Institute for Viral Disease Control and Pre-
vention, China CDC, under protocol 2009ZX10004–101.
To verify the changes of complement in the CSF of
sCJD patients according to the proteomic code, we
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reviewed 37 CSF samples from probable sCJD patients
who tested positive for 14–3–3 protein in their CSF and
typical periodical sharp-wave complexes (PSWC) in their
EEG. We also analyzed 36 CSF samples from non-CJD
patients, who were CSF 14–3–3 negative and had normal
levels of EEG. These samples were taken from the CSF
bank in the China CJD Surveillance Center (Additional
file 2: Table S1). 50 μl CSF samples were taken from each
group and labeled sCJD or non-CJD, respectively. Further-
more, the CSF samples were further subdivided as such:
136 sCJD, 39 genetic CJD (gCJD), 22 FFI and 145 non-
CJD (Table 1). This allowed us to screen the complement
Table 1 The relevant characteristics of the patients with non-CJD and sCJD, gCJD and FFI
Clinical features non-CJD sCJD gCJD FFI
T188K E200K
Number (n) 145 136 25 14 22
Gender (M/F) 71/74 72/64 16/9 7/7 9/13
Median age at onset (range) (y) 61 (45–89) 65 (47–81) 50 (40–85) 56 (44–68) 47.5 (19–63) a
Age at onset <50 years (%) 7(4.8) 3 (2.2) 2 (8) 4 (28.6) 12 (54.5)
Age at onset 50–70 years (%) 114 (78.6) 96 (70.6) 17 (68) 10 (71.4) 10 (45.5)
Age at onset >70 years (%) 24 (16.6) 37 (27.2) 6 (24) 0 (0) 0 (0)
Patients with PRNP gene sequenced (%) 145 (100) 136 (100) 25 (100) 14 (100) 22 (100)
Codon 129 genotype
Met-Met/Total (%) 143/145 (98.6) 133/136 (97.8) 13/25 (100) 14/14 (100) 22/22 (100)
Met-Val/Total (%) 2/145 (1.4) 3/136 (2.2) 0/25 (0) 0/14 (0) 0/22 (0)
Val-Val/Total (%) 0/145 (0) 0/136 (0) 0/25 (0) 0/14 (0) 0/22 (0)
EEG Typical/Total (%) 9/145 (6.2) 92/136 (67.6) b 3/25 (12) 8/14 (57.1) b 0/22 (0)
14–3–3 Positive/Total (%) 29/145 (20) 99/136 (72.8) b 18/25 (72) b 14/14 (100) b 6/22 (27.2)
Progressive dementia/Total (%) 121/145 (83.4) 128/136 (94.1) b 20/25 (80) 13/14 (92.9) 17/22 (77.3)
Myoclonus (%) 33/145 (22.8) 106/136 (77.9) b 15/25 (60) b 10/14 (71.4) b 12/22 (54.5) b
Visual or cerebellar disturbance (%) 22/145 (15.2) 88/136 (64.7) b 18/25 (72) b 11/14 (78.6) b 11/22 (50) b
Pyramidal or extramidal dysfunction (%) 70/145 (48.3) 104/136 (76.5) b 19/25 (76)c 12/14 (85.7) c 13/22 (59.1)
Akinetic mutism (%) 24/145 (16.6) 66/136 (48.5) b 10/25 (40)c 8/14 (57.1) b 3/22 (13.6)
a compared with non-PrD controls by Mann–Whitney U test and the superscript of “a” means P < 0.01
b/c compared with non-PrD controls through Chi-Square test and the superscript of “b” represents p < 0.01 and that of “c” indicates P < 0.05
Table 2 Comparison of the complement proteins in CSF between the groups of probable sCJD and non-CJD in proteomic assay [11]
No. Complement components UniProt accession MW (KDa) Fold of change P-value
1 Complement C4-B P0C0L5 193 0.67 5.62E−04
2 Complement component C7 P10643 94 0.55 5.84E−04
3 Complement C2 P06681 83 0.53 3.72E−03
4 Complement component C9 P02748 63 0.5 1.07E−07
5 Complement factor B P00751 86 0.34 1.78E−04
6 Complement C1s subcomponent P09871 77 0.83 5.39E-03
7 Complement C1q subcomponent subunit C P02747 26 0.71 6.24E-03
8 Complement component C6 P13671 105 0.70 5.84E-03
9 Complement factor H-related protein 1 Q03591 38 0.70 6.53E-03
10 Complement C5 P01031 188 0.67 5.62E-04
11 Complement C1r subcomponent-like protein Q9NZP8 53 0.63 1.18E-03
12 Complement component C8 beta chain P07358 67 0.58 8.73E-04
13 Complement factor H P08603 139 0.55 7.78E-04
14 Complement factor I P05156 66 0.55 5.84E-04
15 Complement C1q subcomponent subunit B P02746 27 0.53 5.77E-04
16 Complement C3 P01024 187 0.13 4.43E-05
17 Complement decay-accelerating factor P08174 41 0.90 4.35E-01
18 Complement C1r subcomponent P00736 80 0.88 1.13E-01
19 Complement component C8 gamma chain P07360 22 0.79 2.79E-01
20 Complement component C8 alpha chain P07357 65 0.73 1.16E-01
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activity individually. The possible clinical diagnoses of
those 145 non-CJD cases were summarized in Additional
file 3: Table S2.
All enrolled CSF samples were obtained by standard
clinical procedures and were free of blood contamination.
Routine CSF biochemistry assays of those specimens,
including cell count, glucose, and total protein were all
within the normal ranges.
The detection of the 50 % of complement hemolytic ac-
tivity (CH50, U/ml) in CSF (50 μl of each tested sample)
was derived from the commercial double-antibody sand-
wich enzyme-linked immunosorbent assays (ELISAs, YAD,
China). Western blots for the complement components
C3a/α, C4β and C9 in the panels of the pooled CSF (20 μl
of each tested sample) were conducted using anti-C3a/α
mAbs (sc-47688), anti-C4β pAbs (sc-25816) and anti-C9
mAbs (sc-390000) (Santa Cruz biotechnology Inc). The de-
tailed procedures of CH50 ELISA and Western blot are de-
scribed elsewhere [5]. The data was processed with
GraphPad Prism 5 and SAS 9.2 statistics software.
Findings
Based on the raw data of our previous study [13], we
identified 20 complement-related components that were
differentially expressed in the sCJD group (Table 2). All
those identified complement components in the CSF of
the sCJD group were down-regulated compared with
Fig. 1 Indirect ELISAs which indicate 50 % of complement
hemolytic activity (CH50, U/ml) in the pooled CSF samples of sCJD
and non-PrDs subjects. The vertical axis represents the unit of CH50.
The results are calculated with data from three independent assays
and presented as mean ± SEM
Fig. 2 Evaluation of the levels of three key complement subunits in the pooled CSF of sCJD and non-CJD subjects. a Western blots of the CSF
panels of sCJD and non-CJD subjects using C3a/α, C4β, and C9-specific antibodies. Albumin in CSF was used as an internal control. b Quantitative
analyses of the averaged gray values normalized with the albumin of individual panels are shown below. The average gray values are calculated
with the data of three independent assays and presented as mean ± SD
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those of non-CJD group, among which were 16 proteins
that showed significant statistical difference (P < 0.01). 5
out of 20 complement components were statistically dif-
ferent at the 95 % confidence interval (gray box in
Table 2) by the Peptide Prophet algorithm [14], includ-
ing C4-B, C7, C2, C9 and factor B.
To obtain more evidence for the alteration of comple-
ment activity and complement components in the CSF of
sCJD patients, CH50 in the CSF panels of sCJD and non-
CJD (protein concentration: 283 ± 15 mg/l for the sCJD
panel and 315 ± 23 mg/l for the non-CJD panel) were ana-
lyzed using a commercial indirect ELISA kit. Compared
with the panel of non-CJD, CH50 in the sCJD panel was
significantly lower (Fig. 1, P < 0.001). Furthermore, the de-
creased levels of three key subunits of complement C3a/α,
C4β, and C9 in complement cascades in the CSF panel of
sCJD were observed by Western blots (Fig. 2).
To evaluate CH50 activity in the CSF of PrD patients,
CSF samples from 197 cases of various PrDs and 145
CSF samples from non-PrDs were given CH50 assays
separately. As shown in Fig. 3, the median CSF CH50
values in the group of sCJD, T188K-gCJD, E200K-gCJD,
and FFI were significantly lower than that of non-CJDs.
Further analysis showed that the CH50 values in 49.3 %
(67/136) of sCJDs, 92.0 % (23/25) of T188K gCJDs,
100 % (14/14) E200K gCJDs, and 77.3 % (17/22) of FFI
were below 100 U/ml, whereas only 28.3 % (41/145) of
non-CJD were in this zone (Table 3). This data indicates
a profile of lower CH50 values in the CSF of PrD pa-
tients. Unlike the wide distribution of CH50 in samples
taken from sCJD and non-CJD groups, the distribution
of CSF CH50 values in T188K-, E200K-gCJD, and FFI
were much narrower. Additionally, the CSF CH50 values
do not correspond with the intervals from the aforemen-
tioned diseases onset to sampling in all tested groups
(Additional file 4: Table S3). Nor do they influence the
survival time of the 31 sCJD patients (Additional file 5:
Figure S1).
To address the potential factor(s) correlated with the CSF
CH50 activity, some clinical and laboratory parameters
from the enrolled patients were statistically analyzed. Uni-
variate analysis illustrated a significant correlation between
14–3–3 and CH50 (Table 4, P = 0.003). Further multivariate
logistic regression proposed that only the presence of 14–
3–3 in CSF showed the notable correlation with CSF CH50
activity (P = 0.004). To further evaluate the relationship be-
tween CH50 activity and 14–3–3 positive CSF, all enrolled
cases were grouped depending if they were 14–3–3 posi-
tive or negative. As shown in Fig. 4, in the context of 342
tested samples, the CSF CH50 values of the cases that
were 14–3–3 positive (median: 86.03 U/ml) were clearly
lower than those that were 14–3–3 negative (median:
143.6 U/ml) (P < 0.0001). Subsequent assays based on vari-
ous diagnoses illustrated lower CSF CH50 activity in the
sCJD cases that were 14–3–3 positive (P < 0.0001). Non-
CJD cases that tested 14–3–3 positive, in contrast, tested
relatively higher without statistical difference (P = 0.545)
(Fig. 4). Lower CH50 values were also detected in the cases
of genetic PrDs that were 14–3–3 positive, but those values
were only significant in the gCJD group (P = 0.0387). This
demonstrates a negative correlation of lower CSF levels and
CH50 activity with 14–3–3 positive PrD patients.
This study has been the first time that lower CSF com-
plements in PrD patients have been observed. The
Fig. 3 Detection of individual CSF levels of the total complement
activity among a sampling of human prion diseases using indirect
ELISAs which indicate 50 % of complement hemolytic activity. The
solid line within each group represents the median of CH50 values.
The P values between the groups of non-CJD subjects and individual
prion diseases are labeled above
Table 3 The numbers of CSF samples among different human prion diseases according to various CH50 value ranges
Groups CH50 (U/ml)
Median (min, max)
P-valuea CH50 (U/ml) % (case No./group No.)
<100 100–200 200–300 >300
non-CJD 154.066 (12.407–480.312) - 28.3 % (41/145) 29.7 % (43/145) 24.1 % (35/145) 17.9 % (26/145)
sCJD 108.55 (4.56–474.40) <0.0001 49.3 % (67/136) 38.2 % (52/136) 7.4 % (10/136) 5.1 % (7/136)
T188K 88.432 (22.39–109.237) 0.0002 92 % (23/25) 8 % (2/25) 0 0
E200K 76.577 (52.03–94.03) <0.0001 100 % (14/14) 0 0 0
FFI 92.905 (21.43–109.70) 0.0012 77.3 % (17/22) 22.7 % (5/22) 0 0
a Mann–Whitney U test
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changes in complement components in CSF have either
decreased [15] or increased [4]. However, the CSF sam-
ples in those studies are not from a healthy control
group, but from patients with various neurological disor-
ders. Activation of the complement system is frequently
detected in the brains of PrD patients. The reason for
this remains unclear, in addition to the relatively silent
complement. It might be assumed that the recruitment
of the large amount of complement components in the
brain [3, 5], such as forming C1q-PrPSc complex [16, 17]
and membrane attack complex (MAC) [5], might lead to
smaller amounts of complement penetrating CSF.
Unlike the wide-range distribution of CSF CH50
values in sCJD, the CH50 values in the three subtypes of
genetic PrDs are low with a narrow range. It indicates a
silent state of the innate immune system in the central
Table 4 Multivarivate logistic regression of the levels of CSF CH50 and relational influence factors
Factors OR 95 % (CI) P-value
Univariate analysis Gender
Male 0.793 (0.456, 1.376) 0.409
Female Reference -
Age of onset
<50 1.260 (0.343, 4.623) 0.728
50–70 1.503 (0.713, 3.169) 0.285
>70 Reference
Codon 129 genotype
Met-Met 1.114 (0.107, 11.648) 0.928
Met-Val Reference
EEG
n.d. 0.231 (0.127, 1.003) 0.272
Positive 0.684 (0.348, 1.346)
Negative Reference
14–3–3 0.003
Positive 0.372 (0.195, 0.707)
Negative Reference
Progressive dementia 0.814
Yes 1.104 (0.485, 2.510)
No Reference
Myoclonus 0.703
Yes 1.137 (0.588, 2.199)
No Reference
Visual or cerebellar disturbance 0.165
Yes 0.639 (0.340, 1.202)
No Reference
Pyramidal or extramidal dysfunction 0.090
Yes 0.602 (0.335, 1.082)
No Reference
Akinetic mutism 0.314
Yes 0.692 (0.337, 1.419)
No Reference
multivarivate logistic regression 14–3–3 0.004
Positive 0.362 (0.182, 0.722)
Negative Reference
n.d. represents not detected
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nervous system during the pathogenesis of genetic PrDs.
In accordance with our previous study, microglia and
some cytokines are silent in the post-mortem brains of
FFI and G114V gCJD cases, while some are obviously
activated in other types of sCJD cases [18]. Recent
iTRAQ-based proteomic study of the brain tissues of
sCJD, FFI, and G114V gCJD show multiple pathways in-
volving immunity and infection in the brains of sCJD
subjects, except for hereditary cases [19]. Additionally,
the diversity of clinical and pathological characteristics
in sCJD may also be contributing factors to the variation
in CH50 present within CSF.
14–3–3 positive CSF samples are the unique factor
correlated with CH50 values found in the CSF of sCJD
patients. The exact molecular association between these
two factors is unknown. Contrary to the well-known
diagnostic evidence for sCJD, the correlation of 14–3–3
CSF samples with brain pathology in CJD are rarely re-
ported, and draw controversial conclusions [20–22]. 14–
3–3 samples are also associated with the alterations of
other proteins in the CSF of sCJD patients. Our recent
publication illustrates that higher levels of tau isoforms
containing Exon-2 and Exon-10 segments in sCJD pa-
tients with 14–3–3 positive CSF [23]. The NSE level in
CSF of sCJD patients is also associated with 14–3–3
positive readings [24]. In that case, one might assume
that 14–3–3 positive CSF samples of sCJD patients cor-
relate with the alterations of CH50 values and other bio-
markers in CSF, thus representing a (sCJD) disease-
associated feature. Nevertheless, the exact molecular
mechanism of 14–3–3 positive and lower CH50 levels in
the CSF of sCJD patients deserves further study.
Conclusions
The complement activities in the CSF of patients with
prion diseases (including sCJD, gCJD, and FFI), are
lower than their non-CJD counterparts are. Additionally,
subjects whose CSF samples tested 14–3–3 positive
exhibit lower complement activity in sCJD patients.
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